|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0025202,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0220825,
umls-concept:C0935987,
umls-concept:C0939537,
umls-concept:C1274040,
umls-concept:C1441616,
umls-concept:C2911684
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-7-21
|
|
pubmed:abstractText |
In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1+ or stronger labelling for CD-117 (up to a maximum of 4+). Three patients with neoplasms showing 4+ staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0960-8931
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
283-5
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16034306-Abdominal Neoplasms,
pubmed-meshheading:16034306-Adult,
pubmed-meshheading:16034306-Antineoplastic Agents,
pubmed-meshheading:16034306-Combined Modality Therapy,
pubmed-meshheading:16034306-Humans,
pubmed-meshheading:16034306-Immunohistochemistry,
pubmed-meshheading:16034306-Male,
pubmed-meshheading:16034306-Melanoma,
pubmed-meshheading:16034306-Middle Aged,
pubmed-meshheading:16034306-Neoplasm Metastasis,
pubmed-meshheading:16034306-Neoplasm Recurrence, Local,
pubmed-meshheading:16034306-Piperazines,
pubmed-meshheading:16034306-Protein Kinase Inhibitors,
pubmed-meshheading:16034306-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:16034306-Pyrimidines,
pubmed-meshheading:16034306-Spinal Neoplasms,
pubmed-meshheading:16034306-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
|
|
pubmed:affiliation |
The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center of Greater Miami and The University of Miami School of Medicine, Miami, FL 33140, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
